louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05268783: Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerk
Official title: Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerk
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Quality of Life
Keywords: neuroendocrine neoplasms
Lead sponsor: University Hospital, Antwerp
Sponsor class: OTHER
First posted: 2022-03-07
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Neuroendocrine tumors (NET) are rare tumors that require specific diagnosis and treatment. Therefore, this poses a challenge for clinical practice. Diagnosis and treatment can be optimized when physician specialists and other healthcare providers, across various hospitals, join forces to provide patients the best care. Based on this idea, a hospital network called NETwerk was set up. The following hospitals are part of this network: University Hospital Antwerp, VITAZ, AZ Monica, AZ Voorkempen, AZ Klina, Gasthuiszusters Antwerpen, Ziekenhuis Netwerk Antwerpen and AZ Rivierenland. In this NETwerk, patients with a neuroendocrine tumor or patients suspected with a neuroendocrine tumor are discussed with the specialists and treated.The aim of this study is to map the quality of life of NET patients within NETwerk in order to optimize the quality of care. Throughout the diagnosis, the treatment process and the follow-up, the patient will be asked to fill out three questionnaires (QLQ-C30, QLQ-GI.NET21 and a satisfaction survey). These questionnaires will be filled out every six months at home. Patients will be asked to complete these questionnaires over a period of five years.


Eligibility criteria: Inclusion Criteria:

* NEN patient
* 18 years or older
* Patient should appear in Oncobase

Exclusion Criteria:

* Patients who do not have an email address

Primary outcomes:
measure: Quality of life measurement with QLQ-C30 questionnaire
timeFrame: 5 years
measure: Quality of life measurement with QLQ-GI.NET21 questionnaire
timeFrame: 5 years
Secondary outcomes:
measure: Quality of care measurement with satisfaction survey
timeFrame: 5 years
Other outcomes:
Locations:
city: Brasschaat
country: Belgium
facility: AZ Klina
state: Antwerp
city: Deurne
country: Belgium
facility: AZ Monica
state: Antwerp
city: Edegem
country: Belgium
facility: Antwerp University Hospital
state: Antwerp
city: Rumst
country: Belgium
facility: AZ Rivierenland
state: Antwerp
city: Sint-Niklaas
country: Belgium
facility: VITAZ
state: East-Flanders
city: Antwerp
country: Belgium
facility: ZNA
city: Antwerp
country: Belgium
facility: GZA
Study officials:
References:
Clinical trial NCT03452683: e-Diary in Heart Failure
Official title: The Use of a Symptom and Weight e-Diary Among Patients With Heart Failure
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Heart Failure
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2018-03-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine the efficacy and feasibility of using a smartphone application to monitor symptoms and weight in patients with advanced heart failure.

Detailed description: Attention to symptoms of heart failure and weight gain are central tenets in heart failure patient education and self-care. A key self-care skill for heart failure patients is the early detection of subtle changes in symptoms. Daily diary use can be one method for patients to acknowledge and attend to their symptoms. This study is examining if the use of a diary in the form of an app on a mobile phone will improve patient outcomes. Participants will be randomized to one of two groups-- usual care or the Movn mobile application. Participants randomized to the mobile app will be asked to record their weight and any symptoms every day over the course of two months.

Eligibility criteria: Inclusion Criteria:

* At least 18 years old
* History of symptomatic heart failure (Class III or IV)
* Owns a smartphone or tablet compatible with the Movn mobile application

Exclusion Criteria:

* Cognitive impairment
* Lack of English proficiency/literacy
* Clinically unstable (decompensated heart failure NYHA class 3-4; unstable arrhythmias, aortic stenosis, thrombophlebitis, dissecting aneurysm, or symptomatic anemia; active infection; uncontrolled blood pressure: resting diastolic higher than 100 mmHg, systolic greater than 180 mmHg; unstable angina, 2nd or 3rd degree heart block; or uncontrolled high grade exercise-induced ventricular ectopy or hemodynamically unstable)

Primary outcomes:
measure: Change in Health Care Utilization
timeFrame: Health Care Utilization will be measured at two timepoints-- baseline and month 3.
Secondary outcomes:
measure: Quality of Life
timeFrame: Quality of life will be measured at two timepoints-- baseline and month 3.
measure: Depression
timeFrame: Depression will be measured at baseline and month 3.
measure: Satisfaction with the app
timeFrame: Satisfaction with the app will be measured at month 3.
Other outcomes:
Locations:
city: Concord
country: United States
facility: John Muir Medical Center
state: California
Study officials:
References:
Clinical trial NCT02420483: Lung Ventilation During Cardiopulmonary Resuscitation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ventilation During Cardiopulmonary Resuscitation
Lead sponsor: University of Thessaly
Sponsor class: OTHER
First posted: 2015-04-17
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The authors to measure passive tidal volumes generated during external chest compressions in order to determine whether chest compressions alone without any mechanical ventilatory support in cardiopulmonary resuscitation can provide adequate ventilation. The authors will study 25 volunteers who meet the following inclusion criteria: age 18-55 years, ASA I-II, candidates for surgical operation, who will receive general anesthesia. Patients who will be operated in the chest, who present musculoskeletal diseases, cardiopulmonary or vascular acute or chronic diseases, who had history of pneumothorax, of thromboembolism, osteoporosis, menopause, history of current rib or sternal or clavicle fractures, will be excluded. All eligible patients will enter the study and will receive general anesthesia and intubation according to treating doctors' decision.

Patients will be ventilated mechanically for 5 minutes to establish stable conditions. A pneumotachograph will be then connected to the ventilatory circuit so that respiratory efforts (volume, airway pressure and flow) can be continuously monitored at real time.

An esophageal catheter will be then inserted to monitor esophageal pressures and to provide data for lung mechanics calculation. Following the above procedures and before any surgical procedure, chest compressions will be performed to the patient by a senior anesthesiologist according to ERC guidelines of 2010 for 30 seconds.

Following chest compressions, patients will be evaluated for possible complications and after the establishment of stable conditions surgical procedures will follow. After the end of the surgical operation clinical and chest ultrasound evaluation will be performed.

Written inform consent will be obtained by all patients before procedures.


Eligibility criteria: Inclusion Criteria:

* age 18-55 years
* ASA I-II
* candidates for surgical operation who will receive general anesthesia

Exclusion Criteria:

* surgical operation in the chest
* musculoskeletal diseases
* cardiopulmonary or vascular acute or chronic diseases
* history of pneumothorax
* thromboembolism
* osteoporosis menopause history of current rib or sternal or clavicle fractures

Primary outcomes:
measure: Tidal volume during cardiopulmonary resuscitation
timeFrame: 30 seconds
Secondary outcomes:
measure: Esophageal pressures during cardiopulmonary resuscitation
timeFrame: 30 seconds
measure: Lung compliance before and at the end of cardiopulmonary resuscitation
timeFrame: 30 seconds
Other outcomes:
Locations:
city: Larissa
country: Greece
facility: Uh Larissa
state: Thessaly
Study officials:
References:
Clinical trial NCT06414083: Histologic Comparison of Ablative Techniques for Endometriosis
Official title: Histologic Comparison of Ablative Techniques for Endometriosis - a Randomized Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Endometriosis
Endometriosis-related Pain
Endometriosis Pelvic
Endometriosis; Peritoneum
Lead sponsor: TriHealth Inc.
Sponsor class: OTHER
First posted: 2024-05-16
Enrollment: 141
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.


Eligibility criteria: Inclusion Criteria:

* Adult women 18 years of age or older
* Already planning to undergo scheduled robotic assisted or laparoscopic excision of lesions for pelvic pain symptoms (pelvic pain, dysmenorrhea, dyspareunia, dysuria, dyschezia, ovarian pain) or endometriosis of any kind (endometriosis of any location, or endometrioma)

Exclusion Criteria:

* Known pregnancy at enrollment or at the time of the excision surgery

Primary outcomes:
measure: Positive Histology
timeFrame: 0 days
Secondary outcomes:
measure: Pelvic Pain
timeFrame: 3 months
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Good Samaritan Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT01597583: MobileMedMinder: A Networked Aide for Medication Compliances
Official title: MobileMedMinder: A Networked Aide for Medication Compliances
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure, Congestive
Lead sponsor: University of Maryland, Baltimore
Sponsor class: OTHER
Collaborators: name: Limaging
First posted: 2012-05-14
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The main aim of this study is to conduct a randomized control trial to compare MobileMedMinder, a mobile phone based medication reminder software product, with currently accepted and empirically supported methods for increasing medication compliance through reminders and tracking.


Eligibility criteria: Inclusion Criteria:

* Taking beta blockers, ACE or ARB, and hydralazine for treatment of HF.

Exclusion Criteria:

* Inability to understand informed consent
* Inability to read and understand English

Primary outcomes:
measure: Compliance
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: University of Maryland
state: Maryland
Study officials:
References:
Clinical trial NCT06932783: Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
Official title: RESTORE: Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Cirrhosis
Keywords: Transcutaneous Electrical Acustimulation
Chronic Pain
Depression
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2025-04-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomized 1:1 to either TEA or sham-control. At least half of the participants will have depression per study definition.
Primary purpose: TREATMENT

Brief summary: This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression.

Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of cirrhosis - must meet the criteria as outlined in the protocol
* Chronic pain (Patient self-reports ≥ 4 on the 0-10 scale for \>50% of days within 3- months)
* Depression (in at least half of participants) - must meet the criteria as outlined in the protocol
* English speaking
* Willing to use a Transcutaneous Electrical Acustimulation device

Exclusion Criteria:

* Dementia and/or severe cognitive impairment
* Unable or unwilling to provide consent
* Expected to undergo liver transplant in next 24 weeks
* No email address
* Deemed unsuitable by the study investigator

Primary outcomes:
measure: Acceptability Questionnaire at 10 weeks
timeFrame: 10 weeks
measure: Feasibility based on the proportion of participants enrolled that were contacted
timeFrame: Enrollment period (2 years)
measure: Feasibility based on the Proportion of enrolled participants that dropout (overall and during run in)
timeFrame: Run-in (-14 days to baseline) to 10 weeks
measure: Feasibility based on time required to complete study assessments
timeFrame: Screening - 10 weeks
measure: Proportion of questionnaires completed at baseline and the final study visit (10 weeks)
timeFrame: Baseline, 10 weeks
measure: TEA usage during the intervention period
timeFrame: Weeks 1-8 of TEA treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Elliot Tapper, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05784883: Tricuspid Regurgitation in the ElderlY
Official title: Prevalence, Mechanisms, and Outcome of Tricuspid Valve Regurgitation in the Elderly
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Tricuspid Regurgitation
Keywords: Valvular heart disease
Tricuspid regurgitation
Elderly
Geriatric
Echocardiography
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2023-03-27
Enrollment: 700
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients ≥ 60 years old presenting to the echocardiography clinic.

Brief summary: Tricuspid regurgitation (TR) is the second most common VHD after MR. Its prevalence also increases with age, with an estimated incidence of up to 6% in elderly population. When adjusted to age (among other confounders), survival is worse for patients with moderate and severe TR. We aim to explore the prevalence, mechanisms, and clinical implications of tricuspid valve regurgitation in elderly subjects screened at a tertiary center in Cairo, Egypt.


Eligibility criteria: Inclusion Criteria:

* All comer patients ≥60-year-old presenting to the echocardiography clinic

Exclusion Criteria:

* Poor acoustic window.

Primary outcomes:
measure: Prevalence of tricuspid valve regurgitation in the elderly
timeFrame: Baseline (at enrolment)
measure: All-cause mortality
timeFrame: At 6 months
measure: Cardiovascular mortality
timeFrame: At 6 months
measure: Rehospitalization for congestive heart failure
timeFrame: At 6 months
Secondary outcomes:
measure: Classification of tricuspid valve regurgitation in the elderly
timeFrame: Baseline
measure: Change in New York Heart Association (NYHA) functional class
timeFrame: At 6, 12 and 60 months
measure: All-cause mortality
timeFrame: At 12 and 60 months
measure: Cardiovascular mortality
timeFrame: At 12 and 60 months
measure: Rehospitalization for congestive heart failure
timeFrame: At 12 and 60 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al Hussein University Hospital of Al-Azhar University
Study officials:
affiliation: Al-Azhar Cardiology Research Institute
name: Mohammad Abdelghani, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01584583: Blood Pressure Monitor Clinical Test (Cuff Range: 22 Cm-36cm)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Blood Pressure
Keywords: BP
Lead sponsor: Andon Health Co., Ltd
Sponsor class: INDUSTRY
First posted: 2012-04-25
Enrollment: 85
Sex: ALL
Minimum age (years): 24
Maximum age (years): 81
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: resident of a community

Brief summary: The purpose of this study is to monitor the blood pressure level of the patient using a preformed cuff ranged 22 cm-36 cm.


Eligibility criteria: Inclusion Criteria:

* cuff circumference: 22cm-36cm

Exclusion Criteria:

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04102683: The Effects of Therapeutic Recreation Activities on Emotional Adjustment of Individuals With Intellectual Disabilities
Official title: The Effects of Therapeutic Recreation Activities on Emotional Adjustment of Individuals With Intellectual Disabilities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Emotional Adjustment
Intellectual Disability
Keywords: Game
Therapeutic Recreation
Intellectual Disability
Lead sponsor: Selcuk University
Sponsor class: OTHER
First posted: 2019-09-25
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study was to determine the effect of Therapeutic Recreation Activities on Emotional Adjustment of Adolescents With Intellactual Disabilities. The research was carried out at Meram Melike Hatun Special Education Vocational School in Konya. The study took place between March 2019 and May 2019. The parents of the participants who participated in the study consisted of the experimental group (n = 17) and the remaining parents (n = 17) formed the control group and the sample group (n = 34). The personal information form which measures demographic characteristics developed by the researchers according to the literature, and Hacettepe Emotional Adjustment Scale were used. Data were analyzed in SPSS 22 program. According to Kolmogorov-Smirnov Z test, sample group was not normal. For this reason, non-parametric tests were performed. In descriptive data, the mean, number, percentage will be used; Comparative statistics were made according to the assumptions of non-parametric test (Wilcoxon test, Mann Whitney U test). Therapeutic Recreation Activities was applied as total of 16 sessions, consisting of two sessions per week and each session lasting about 1 hour. The program was implemented by researcher.


Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

* Having a physical disability,
* Having Down syndrome

Primary outcomes:
measure: Mental adjustment scale score level
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: Selcuk University
state: Selcuklu
Study officials:
References:
Clinical trial NCT00664183: A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Official title: A Phase 3 Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Diabetic Retinopathy
Keywords: diabetic retinopathy
Lead sponsor: Vitreoretinal Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2008-04-22
Enrollment: 400
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.


Eligibility criteria: Inclusion Criteria:

* Subjects with a history of systemic diabetes (type I or II)
* Subject with a documented history of Non Proliferative Diabetic Retinopathy (NPDR)
* Subjects with no PVD at baseline exam in the study eye.

Exclusion Criteria:

* Subjects with Retinal pathology in the study eye other than (NPDR)
* Subjects with high myopia in the study eye
* Subjects who have monocular vision or contra lateral vision of 20/200 or worse BCVA in the non-study eye.
* Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less than 6 months prior to study enrollment
* Subjects that have had either vitrectomy surgery, intravitreal injections, or laser treatments in the study eye.

Primary outcomes:
measure: Ultrasound
timeFrame: 7 Months
Secondary outcomes:
measure: Ultrasound, OCT, Safety
timeFrame: 7 Months
Other outcomes:
Locations:
city: Phoenix
country: United States
state: Arizona
city: Beverly Hills
country: United States
state: California
city: Santa Ana
country: United States
state: California
city: Gainesville
country: United States
state: Florida
city: Lakeland
country: United States
state: Florida
city: Indianapolis
country: United States
state: Indiana
city: New Albany
country: United States
state: Indiana
city: Asheville
country: United States
state: North Carolina
city: McAllen
country: United States
state: Texas
city: Silverdale
country: United States
state: Washington
city: Bhubhneshwar
country: India
facility: LVPEI
city: Chennai
country: India
facility: Sankara Nethralaya
city: Coimbatore
country: India
facility: Aravind
city: Delhi
country: India
facility: AIIMS
city: Hyderabad
country: India
facility: LVPEI
city: Madurai
country: India
facility: Aravind
city: Pondicherry
country: India
facility: Aravind
Study officials:
affiliation: University of California, Irvine
name: Baruch Kupperman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Colorado, Denver
name: Naresh Mandova, MD
role: PRINCIPAL_INVESTIGATOR
References: